Metabolite concentrations and H. pylori risk in GC cases and FDR controls
Serum pepsinogen 2 (sPG2) level is one of the predictive parameters for gastric cancer (GC) risk but factors that regulate change in PG2 expression are still unknown. Aim of the present study was to investigate genetic variants that may regulated PG2 expression in patients with GC or at risk for GC.
Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype
The CDH1 gene, coding for the E-cadherin protein, is linked to gastric cancer (GC) susceptibility and tumor invasion. The human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in a portion of GC.
Helicobacter pylori treatment effectiveness in developing countries: A network meta-analysis
Helicobacter pylori is a putative risk factor for peptic ulcers and gastric cancer. Current treatment guidelines for H pylori are based on results from developed countries.
Prevalence of infection and Antimicrobial Resistance of Helicobacter pylori isolates from symptomatic patients of Talca Regional Hospital, Chile
Helicobacter pylori, is the causative agent of gastritis, gastric ulcers, gastric cancer and mucosal-associated lymphoid tissue tumor (MALT). There are several treatment schemes for the eradication of this bacterium.
Sequencing of the cag Pathogenicity Island and vacA gene by next generation sequencing directly from gastric mucosa DNA
To date, analysis of the complete cag Pathogenicity Island and vacA gene have been carried out mainly by whole genome sequencing of H.pylori strains obtained by culture.
Polymorphisms in Wnt/beta-catenin pathway are associated with survival of gastric cancer
Gastric cancer (GC) is the sixth most common cancer and the third leading cause of death due to cancer worldwide. More than a half of patients are diagnosed at advanced stage (TNM III), where 5-year overall survival rate is less than 50%.